China Jo-Jo Drugstores, Inc. (CJJD)
USD 1.82
(0.91%)
USD 1.82
(0.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -3.53 Million USD | 66.55% |
| 2023 | -10.56 Million USD | -315.13% |
| 2022 | -2.54 Million USD | 70.44% |
| 2021 | -8.6 Million USD | -35.03% |
| 2020 | -6.37 Million USD | -1059.87% |
| 2019 | -549.67 Thousand USD | 96.66% |
| 2018 | -16.43 Million USD | -312.9% |
| 2017 | -3.98 Million USD | -15975.01% |
| 2016 | -24.76 Thousand USD | -101.45% |
| 2015 | 1.7 Million USD | 108.88% |
| 2014 | -19.23 Million USD | -36.81% |
| 2013 | -14.05 Million USD | -234.09% |
| 2012 | 10.48 Million USD | -9.48% |
| 2011 | 11.57 Million USD | -9.23% |
| 2010 | 12.75 Million USD | 44477.19% |
| 2009 | -28.74 Thousand USD | -669.28% |
| 2008 | -3737.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -1.89 Million USD | 0.0% |
| 2024 Q2 | 127.99 Thousand USD | 0.0% |
| 2024 FY | -3.53 Million USD | 66.55% |
| 2024 Q3 | -1.89 Million USD | -1580.79% |
| 2024 Q1 | 127.99 Thousand USD | 101.3% |
| 2023 Q2 | -622.34 Thousand USD | 0.0% |
| 2023 Q1 | -622.34 Thousand USD | 69.68% |
| 2023 Q3 | -9.84 Million USD | -1481.18% |
| 2023 Q4 | -9.84 Million USD | 0.0% |
| 2023 FY | -10.56 Million USD | -315.13% |
| 2022 Q2 | -492.31 Thousand USD | -100.0% |
| 2022 Q3 | -1.02 Million USD | -108.49% |
| 2022 Q4 | -2.05 Million USD | -100.0% |
| 2022 Q1 | -246.15 Thousand USD | -260.35% |
| 2022 FY | -2.54 Million USD | 70.44% |
| 2021 FY | -8.6 Million USD | -35.03% |
| 2021 Q1 | -198.74 Thousand USD | 93.75% |
| 2021 Q3 | -6.36 Million USD | -317.74% |
| 2021 Q4 | 153.5 Thousand USD | 102.41% |
| 2021 Q2 | -1.52 Million USD | -666.97% |
| 2020 FY | -6.37 Million USD | -1059.87% |
| 2020 Q4 | -3.18 Million USD | -675.41% |
| 2020 Q3 | 552.91 Thousand USD | 134.21% |
| 2020 Q2 | -1.61 Million USD | 41.41% |
| 2020 Q1 | -2.75 Million USD | -179.82% |
| 2019 Q4 | 3.45 Million USD | 262.59% |
| 2019 Q2 | -1.64 Million USD | -190.76% |
| 2019 FY | -549.67 Thousand USD | 96.66% |
| 2019 Q3 | -2.12 Million USD | -29.46% |
| 2019 Q1 | -564.7 Thousand USD | 95.56% |
| 2018 Q2 | -1.64 Million USD | -12.57% |
| 2018 FY | -16.43 Million USD | -312.9% |
| 2018 Q1 | -1.46 Million USD | 50.7% |
| 2018 Q3 | -2.18 Million USD | -32.66% |
| 2018 Q4 | -12.72 Million USD | -481.61% |
| 2017 Q3 | -838.16 Thousand USD | -1482.48% |
| 2017 FY | -3.98 Million USD | -15975.01% |
| 2017 Q4 | -2.97 Million USD | -254.42% |
| 2017 Q2 | -52.96 Thousand USD | 55.64% |
| 2017 Q1 | -119.39 Thousand USD | -158.1% |
| 2016 Q4 | 205.49 Thousand USD | 166.77% |
| 2016 Q2 | -281.59 Thousand USD | -178.42% |
| 2016 Q3 | -307.75 Thousand USD | -9.29% |
| 2016 FY | -24.76 Thousand USD | -101.45% |
| 2016 Q1 | 359.08 Thousand USD | -77.36% |
| 2015 Q4 | 1.58 Million USD | 322.19% |
| 2015 Q2 | 85.3 Thousand USD | 125.15% |
| 2015 Q1 | -339.15 Thousand USD | 96.28% |
| 2015 FY | 1.7 Million USD | 108.88% |
| 2015 Q3 | 375.73 Thousand USD | 340.48% |
| 2014 Q2 | -522.7 Thousand USD | 27.45% |
| 2014 Q3 | -8.85 Million USD | -1594.97% |
| 2014 Q4 | -9.12 Million USD | -3.02% |
| 2014 Q1 | -720.49 Thousand USD | 93.46% |
| 2014 FY | -19.23 Million USD | -36.81% |
| 2013 Q2 | 9263.00 USD | -97.89% |
| 2013 Q4 | -11.01 Million USD | -215.75% |
| 2013 Q3 | -3.48 Million USD | -37765.23% |
| 2013 Q1 | 439.97 Thousand USD | 102.28% |
| 2013 FY | -14.05 Million USD | -234.09% |
| 2012 Q4 | -19.27 Million USD | -995.6% |
| 2012 FY | 10.48 Million USD | -9.48% |
| 2012 Q3 | 2.15 Million USD | -3.3% |
| 2012 Q2 | 2.22 Million USD | -49.6% |
| 2012 Q1 | 4.41 Million USD | 32.75% |
| 2011 Q1 | 3.01 Million USD | -37.5% |
| 2011 Q4 | 3.32 Million USD | 20.34% |
| 2011 Q3 | 2.76 Million USD | 11.87% |
| 2011 FY | 11.57 Million USD | -9.23% |
| 2011 Q2 | 2.47 Million USD | -18.08% |
| 2010 FY | 12.75 Million USD | 44477.19% |
| 2010 Q4 | 4.82 Million USD | 41.43% |
| 2010 Q2 | 2.33 Million USD | 198486.24% |
| 2010 Q3 | 3.41 Million USD | 46.0% |
| 2010 Q1 | 1177.00 USD | 127.62% |
| 2009 Q4 | -4261.00 USD | 22.37% |
| 2009 Q1 | -4001.00 USD | 76.2% |
| 2009 Q3 | -5489.00 USD | -380.23% |
| 2009 FY | -28.74 Thousand USD | -669.28% |
| 2009 Q2 | -1143.00 USD | 71.43% |
| 2008 Q2 | -859.00 USD | 0.0% |
| 2008 Q4 | -16.8 Thousand USD | -137.45% |
| 2008 FY | -3737.00 USD | 0.0% |
| 2008 Q3 | -7079.00 USD | -724.1% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -13.47 Million USD | 73.774% |
| BIMI International Medical Inc. | -15.33 Million USD | 76.956% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 580 Thousand USD | 709.407% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 431 Thousand USD | 920.084% |
| Leafly Holdings, Inc. | -7.05 Million USD | 49.871% |
| Leafly Holdings, Inc. | -7.05 Million USD | 49.871% |
| LifeMD, Inc. | -14.48 Million USD | 75.606% |
| LifeMD, Inc. | -14.48 Million USD | 75.606% |
| TRxADE HEALTH, Inc. | -7.26 Million USD | 51.337% |
| PetMed Express, Inc. | -8.16 Million USD | 56.695% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.975% |